Centene Corporation (LON:0HVB)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 23.72B +154.0% |
| Revenue (ttm) | 135.90B +12.9% |
| Net Income | -3.84B |
| EPS | -7.81 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 13.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,721 |
| Open | 65.87 |
| Previous Close | 65.69 |
| Day's Range | 64.53 - 65.94 |
| 52-Week Range | 25.27 - 70.50 |
| Beta | 1.11 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 28, 2026 |
About Centene
Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment offers the temporary assistance for needy families; medicaid expansion; aged, blind, or disabled; and children's health insurance programs, as well as long-term services and supports; foster care; and medicare-medicaid plans. This segment also provides healthcare products and servi... [Read more]
News
Health Net Providing Special Assistance to Members and Providers Affected by Gann Fire in Calaveras County
SACRAMENTO, Calif., Aug. 11, 2026 /PRNewswire/ -- Following Gov.
Centene upgraded to Buy from Hold at Argus
Argus upgraded Centene (CNC) to Buy from Hold.
Centene upgraded to Buy at Argus on margin expansion potential
Argus upgraded Centene (CNC) to Buy from Hold with an $80 price target The company appears positioned to reach its prior margin targets over the next few years as Medicaid…
Superior HealthPlan and Centene Foundation Make $350,000 Investment to Help with Flood Relief in Texas
The investment helps five local organizations respond to historic flooding across the Hill Country and South-Central Texas AUSTIN, Texas, Aug. 5, 2026 /PRNewswire/ -- Superior HealthPlan and Centene F...
Centene price target raised to $67 from $60 at JPMorgan
JPMorgan raised the firm’s price target on Centene (CNC) to $67 from $60 and keeps a Neutral rating on the shares.
Centene price target raised to $79 from $68 at Bernstein
Bernstein analyst Lance Wilkes raised the firm’s price target on Centene (CNC) to $79 from $68 and keeps an Outperform rating on the shares. The firm cites Q2 results and…
Centene price target raised to $66 from $57 at Morgan Stanley
Morgan Stanley analyst Erin Wright raised the firm’s price target on Centene (CNC) to $66 from $57 and keeps an Equal Weight rating on the shares. The risk-reward for Centene…
Centene price target raised to $70 from $61 at UBS
UBS raised the firm’s price target on Centene (CNC) to $70 from $61 and keeps a Neutral rating on the shares.
Centene price target raised to $78 from $74 at BofA
BofA analyst Kevin Fischbeck raised the firm’s price target on Centene (CNC) to $78 from $74 and keeps a Buy rating on the shares. The “most important datapoint” from the…
Centene price target raised to $66 from $46 at Baird
Baird raised the firm’s price target on Centene (CNC) to $66 from $46 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results where…
Centene price target raised to $80 from $75 at Barclays
Barclays analyst Andrew Mok raised the firm’s price target on Centene (CNC) to $80 from $75 and keeps an Overweight rating on the shares. The firm updated the company’s model…
Centene Earnings Call Transcript: Q2 2026
Q2 results exceeded expectations with adjusted EPS of $2.51 and strong performance across all segments. 2026 guidance was raised, driven by improved Marketplace and Medicare margins, operational efficiencies, and disciplined cost management. Medicaid membership attrition and regulatory changes remain key watch areas.
Centene Quarterly report: Q2 2026
Centene has published its Q2 2026 quarterly earnings report on July 28, 2026.
Centene Earnings release: Q2 2026
Centene released its Q2 2026 earnings on July 28, 2026, summarizing the period's financial results.
Centene Reports $1 Billion Profit As Health Insurer's Costs Ease
Health insurer Centene's net income eclipsed $1 billion in the second quarter as the company is getting a better handle on rising costs of people in its commercial and government-subsidized health pla...
Centene Raises 2026 Outlook on Profit, Revenue Growth
Centene lifted its guidance for the year after revenue and profit growth in the second quarter were driven by strength in its core government-sponsored and individual healthcare lines.
Centene ups FY26 adjusted EPS view to greater than $4.80 from greater than $3.40
Consensus $3.52. Raises FY26 revenue view to $193.5B-$197.5B from $187.5M-$191.5M, consensus $190.33B. Lowers FY26 adjusted effective tax rate view to 25.5%-26.5% from 26%-27%. The company said, “The ...
Centene reports Q2 adjusted EPS $2.51, consensus $1.08
Reports Q2 revenue $53.58B, consensus $47.45B. “Our second quarter results and improved full-year outlook represent meaningful milestones on our path to restoring profitability and increasing sharehol...
Centene raises annual profit forecast on better cost control
Centene on Tuesday raised its annual profit forecast, as the health insurer kept control of its costs.
CENTENE CORPORATION REPORTS SECOND QUARTER 2026 RESULTS
-- Second Quarter GAAP Diluted Earnings Per Share of $2.19; Adjusted Diluted Earnings Per Share of $2.51 -- -- Increases 2026 GAAP Diluted EPS Guidance: Greater than $3.11 & Adjusted Diluted EPS Great...
CENTENE ANNOUNCES BOARD OF DIRECTORS CHANGES
ST. LOUIS, July 28, 2026 /PRNewswire/ -- Centene Corporation (NYSE: CNC) today announced that Kenneth A. Burdick has retired from the Company's Board of Directors, effective July 28, 2026, and that Pa...
UnitedHealth Earnings Crush Estimates and Give These Stocks a Boost
The healthcare giant posts better-than-expected second-quarter earnings and hikes its full-year guidance.
Centene price target raised to $65 from $47 at TD Cowen
TD Cowen analyst Ryan Langston raised the firm’s price target on Centene (CNC) to $65 from $47 and keeps a Hold rating on the shares. The firm adjusted targets in…
Centene price target raised to $78 from $71 at Truist
Truist analyst David MacDonald raised the firm’s price target on Centene (CNC) to $78 from $71 and keeps a Buy rating on the shares as part of a broader research…
Centene price target raised to $69 from $56 at Wells Fargo
Wells Fargo raised the firm’s price target on Centene (CNC) to $69 from $56 and keeps an Equal Weight rating on the shares. The firm’s outlook for Healthcare Services earnings…